ARCHIVES

MGI Pharma’s Irofulven In Phase III Trial Vs. 5-FU For Advanced Pancreatic Cancer.

This article is from The Cancer Letter archive.

Vol. 27 No. 09 | March 2, 2001

Download PDF Visit The Full Archive

Related Articles

Recombinant Protein C Cuts Risk Of Sepsis Death

February 22, 2002

In Brief: Panel to Meet Jan. 30 In Los Angeles; Fate Of Proposed Urologic Group Depends On Budget

January 10, 1986

DeVita, Moertel Debate Timing Of Levamisole Update

February 16, 1990

NCI Ponders Options for Implementing NCAB Changes In Organ Site Program

June 4, 1982

Studies Seek to Identify High-Risk Groups to Justify Mammography Screening at 40

May 4, 2012

Professional Fundraiser Poses Eight Questions For SU2C 3.

September 19, 2008